Paclitaxel-induced systemic sclerosis
DOI:
https://doi.org/10.32818/reccmi.a3n2a3Keywords:
scleroderma, taxoids, interstitial lung diseases.Abstract
Taxanes are effective antineoplastic drugs against different solid tumors. Its use has been related to the development of scleroderma like skin lesions which in some patients are accompanied by visceral involvement, Raynaud, capillary alterations and positivitation of antibodies. We present the case of a patient who, after receiving paclitaxel for an ovarian neoplasia, develops a systemic scleroderma with rapidly evolving interstitial pulmonary involvement.
Downloads
Metrics
References
Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013; 65: 2737-2747.
Bielopolski D, Evron E, Moreh-Rahav O, et al. Paclitaxel induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother. 2017; 29(2): 113-117.
Holmes FA, Walters RS, Theriault BHL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst. 1991; 83: 1797-1805.
Sibaud V, Leboeuf NR, Roche H, et al. Dermatological adverse events with taxane chemotherapy. Eur J Dermatol. 2016; 26: 427-443.
Battafarano DF, Zimmerman GC, Older SA, et al. Docetaxel (taxotere) associated scleroderma like changes of the lower extremities. A report of three cases. Cancer. 1995; 76: 110-115.
Läuchli S, Trüeb RM, Fehr, et al. Scleroderma like drug reaction to paclitaxel (Taxol®). Br J Dermatol. 2002; 147: 619-621.
Takahashi T, Asano Y, Ichimura Y, et al. A case of taxane induced scleroderma: a different expression profile of Fli1 proteins in dermal fibroblasts and microvascular endothelial cells compared with systemic sclerosis. Br J Der- matol. 2011; 164: 1393-1395.
Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017; 76: 1327-1339.
Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma related intesrttial disease (SLS-II): a randomised controlled, double blind, parallel group trial. Lancet Respir Med. 2016; 4: 708-719.
Clevelan MG, Ajaikumar BS, Reganti R. Cutaneous fibrosis induced by doce taxel. Cancer. 2000; 88: 1078-1081.
Hassett G, Harnett P, Manolios N. Scleroderma in association with the use of docetaxel (taxotere) for breast cáncer. Clin Exp Rheumatol. 2001; 19: 197- 200.
De Angelis R, Bugatti L, Cerioni A, et al. Diffuse scleroderma occurring after the use of paclitaxel for ovarian cancer. Clin Rheumatol. 2003; 22: 49-52.
Kupfer I, Balguerie X, Courville P, et al. Scleroderma like cutaneous lesions induced by paclitaxel: a case study. J Am Acad Dermatol. 2003; 48: 279-281.
Farrant PBJ, Mortimer PS, Gore M. Scleroderma and the taxanes. Is there really a link? Clin Exp Dermatol. 2004; 29: 360-362.
Itoh M, Yanaba K, Kobayashi T, et al. Taxane induced scleroderma. Br J Der- matol. 2007; 156: 363-367.
Kawakami T, Tsutsumi Y, Soma Y. Limited cutaneous systemic sclerosis induced by paclitaxel in a patient with breast cancer. Arch Dermatol. 2009; 145: 97-98.
Vitfell Pedersen J, Jensen S, Krarup-Hansen A, et al. Scleroderma induced by paclitaxel. Acta Oncol. 2010; 49: 866-868.
Kılıç MÖ, Yalaza M, Bilgiç Cİ, Dener C. Docetaxel induced scleroderma in a breast cancer patient: a case report. J Breast Health. 2015; 11: 95-97.
Winkelmann RR, Yiannias JA, DiCaudo DJ, et al. Paclitaxel induced diffuse cutaneous sclerosis: a case with associated esophageal dysmo- tility, Raynaud’s phenomenon, and myositis. Int J Dermatol. 2016; 55: 97-100.
Yang JQ, Dou TT, Chen XB, et al. Docetaxel induced scleroderma: a case report and its role in the production of extracellular matrix. Int J Rheum Dis. 2017; 20: 1835-1837.
Park B, Vemulapalli RC, Gupta A, et al. Docetaxel induced systemic sclerosis with internal organ involvement masquerading as congestive heart failure. Case Reports Immunol. 2017; 2017: 4249157.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 Laura González-Vázquez, Ana Cobas-Paz, Luisa Valle-Feijóo, Clara Senín-Estor, Javier de la Fuente-Aguado
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
